このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

閉塞性睡眠時無呼吸症候群患者における経皮電気刺激 (TESLA-MICRON)

2026年9月16日 更新者:Zeus Sleep Ltd

Zeus Sleep Technology:閉塞性睡眠時無呼吸症候群患者における経皮的電気刺激を用いた英国拠点の多施設無作為化比較試験 (TESLA)

The objective of this trial is to assess efficacy and compliance of transcutaneous electrical stimulation of the upper airway dilator muscles in patients with obstructive sleep apnoea (TESLA) who do not tolerate continuous positive airway pressure (CPAP) therapy over a period of 3-months in the community and compare results against usual care (ongoing CPAP therapy), evaluate acceptability, comfort and adverse events, and record outcomes for provision of the health economics analysis. The proposed study will provide us with data about the efficacy of the domiciliary use of the intervention from a UK-based prospective, multi-centre and randomised controlled trial (Phase III). We will understand whether the primary outcome parameter, the apnoea hypopnea index (AHI), or the secondary outcomes (e.g. 4% oxygen desaturation index (ODI), the Epworth Sleepiness Scale (ESS), compliance and comfort, Functional Outcome of Sleep Questionnaires (FOSQ), European Quality of Life Questionnaire (EQ-5D)) are suitable measures to assess control of OSA using TESLA within reasonable acceptance for the patients to provide the analysis of healthcare resource usage for assessment of cost-efficacy and quality-adjusted life years (QALYs). Responder analysis will provide insights into gender, socio-economic background and endotypes to predict who most suitably benefits from this treatment.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

The TESLA-MICRON study is a UK-based, prospective, multi-centre, randomised controlled trial designed to evaluate the use of an investigational medical device, ZeusOSA, for the treatment of obstructive sleep apnoea in adults with poor adherence to continuous positive airway pressure (CPAP) therapy.

ZeusOSA uses gentle stimulation through the skin similar to that of a TENS machine. The device features a U-shaped lightweight silicone pad with a disposable adhesive hydrogel electrode pad (single-use) that delivers mild transcutaneous electrical nerve stimulation (TENS) to activate the hypoglossal nerve, thereby stimulating muscles to contract, particularly those associated with opening the airways (e.g., genioglossus muscle). Application of regular electrical pulses to these muscles help to maintain an open airway. The upper airway muscles might otherwise relax with sleep onset and cause vibrations and collapse in the throat whilst breathing, manifesting as snoring or sleep apnoea's or hypopneas. The stimulation level is customisable from level 1 (milder stimulation) to level 10 (stronger stimulation).

186 participants will be recruited with a prior diagnosis of obstructive sleep apnoea and low CPAP adherence at follow up (less than 4 hours/night) will be randomly assigned in a 1:1 ratio to either the intervention group or a usual care group. Recruitment will focus on a balanced ratio of men and women, as women are typically under-represented in studies of OSA and, due to a slim neck / collar size in comparison to men, likely to be responders to the TESLA treatment. Participants allocated to the intervention group will use the investigational medical device, ZeusOSA, which delivers transcutaneous electrical stimulation to the upper airway dilator muscles during sleep. The device is intended for nightly use at home over a three-month period. Participants in the usual care group will continue with ongoing CPAP therapy in accordance with current clinical practice.

All participants will undergo baseline assessments prior to randomisation, including a home-based sleep study conducted without treatment. Follow-up will include a scheduled telephone contact at approximately six weeks and a repeat assessment at three months, including a further home-based sleep study conducted with the assigned treatment and receive standard advice on sleep hygiene and lifestyle measures. The patients will then be referred for follow up to standard care in the outpatient setting at their respective sleep centre. The trial duration including recruitment is 3 years.

The study will assess the therapeutic effects of the investigational medical device on sleep-related outcomes and symptoms, as well as participant-reported quality of life. Additional objectives include evaluation of treatment adherence, comfort and acceptability of use, and monitoring of adverse events. Data collected during the study will also be used to support an assessment of healthcare resource use associated with the intervention.

The study is designed to reflect real-world use of the investigational medical device in a domiciliary setting and to identify patient characteristics associated with response to treatment. Results from this trial will inform the future clinical and regulatory development of the device for the management of obstructive sleep apnoea.

研究の種類

介入

入学 (推定)

186

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Salma Ayyis, PhD
  • 電話番号:x82821 +442071882823

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Adult participants (≥18 years) who have OSA with an AHI between 5-40 events/hour, as measured by the baseline sleep study (3 nights off CPAP).
  2. If the participant fails to use CPAP sufficiently, defined as use of CPAP for less than 4 hours/night on fewer than 70% of nights over a minimum period of 3 months prior to enrolment.
  3. Adults with a body mass index (BMI) of 18.5-32.0 kg/m2 (inclusive)
  4. Adults without significant anatomical obstruction in the upper airway (e.g., normal sized tonsils).
  5. Able and willing to provide informed written consent.
  6. Access to a smartphone and internet at home.

Exclusion Criteria:

  1. Hypercapnic patients (pCO2>6.0 kPa) or those with other features of obesity hypoventilation syndrome (elevated bicarbonate, HCO3- >28mmol/L).
  2. Adults with significantly enlarged tonsils (size 3-4)
  3. Adults with polyps or adenoids, hypoglossal nerve palsy,
  4. Adults with notable medical co-morbidities that could potentially impact participation in or the achievement of the study's objectives (e.g., significant heart failure (New York Heart Association, NYHA class III-IV), recent myocardial infarction (within 3 months) and significant cardiac arrhythmias, uncontrolled hypertension).
  5. Participants with an active psychiatric condition that, in the opinion of the Investigator, may affect the participant's capacity to provide informed consent, adhere to study procedures, actively participate in the study, or compromise the integrity of study data.
  6. Participants with active implantable medical devices, including but not limited to cardiac pacemakers, implantable cardioverter defibrillators (ICDs), cochlear implants, deep brain stimulation (DBS) systems, vagus nerve stimulation (VNS) devices, neurostimulators, or implanted infusion pumps.
  7. Participants with metallic implants in the head or neck region that, in the opinion of the Investigator, may interfere with the safe use of the investigational device.
  8. Participants who are physically incapacitated such as to manoeuvre the ZeusOSA device
  9. Adults with long facial hair that interferes with the correct placement of the hydrogel pad, and who are unwilling to shave.
  10. Participants with an allergy to plasters or similar products.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Usual Care

Continuous Positive Airway Pressure (CPAP)

Continous positive airway pressure (CPAP) when asleep

実験的:Intervention

Transcutaneous Electrical Stimulation (ZeusOSA)

Transcutaneous electrical stimulation in sleep apnoea (TESLA) in the submittal area, provided by the ZeusSleep device when asleep.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Apnea-hypopnea-index (AHI)
時間枠:Baseline to 3 months

Number of respiratory events per hour measured by home-based sleep study.

Baseline to 3 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Epworth Sleepiness Scale (ESS)
時間枠:Baseline to 3 months

Daytime sleepiness measured using the Epworth Sleepiness Scale (score range 0-24, with higher scores indicating greater sleepiness).

Baseline to 3 months
EQ-5D Index Score
時間枠:Baseline to 3 months

Health-related quality of life measured using the EQ-5D descriptive system (index score 0-1).

Baseline to 3 months
EQ-5D Visual Analogue Scale (VAS) Score
時間枠:Baseline to 3 months

Self-rated health measured using the EQ-5D visual analogue scale (0-100, with higher scores indicating better perceived health).

Baseline to 3 months
Functional Outcome of Sleep Questionnaire (FOSQ-10) Score
時間枠:Baseline to 3 months

Sleep-related functional status measured using the FOSQ-10, with higher scores indicating better functional outcomes.

Baseline to 3 months
Snoring Duration
時間枠:Baseline to 3 months

Total duration of snoring measured during sleep, expressed in minutes.

Baseline to 3 months
Snoring Intensity
時間枠:Baseline to 3 months

Average snoring intensity measured in decibels during sleep.

Baseline to 3 months
Adherence Average hours/night
時間枠:Baseline to 3 months

Average nightly usage (hours) of the assigned treatment.

Baseline to 3 months
Adherence - Percentage of Nights Used
時間枠:Baseline to 3 months

Percentage of nights the assigned treatment was used during the study period.

Baseline to 3 months
4% ODI (Oxygen Desaturation Index)
時間枠:Baseline to 3 months

ODI refers to the average number of desaturation episodes occurring per hour, where desaturation episodes are defined as a decrease in the mean oxygen saturation of ≥ 4% (over the last 120 seconds) that lasts for at least 10 seconds.

Baseline to 3 months

その他の成果指標

結果測定
メジャーの説明
時間枠
SHER15 criteria defining responders to treatment
時間枠:3-months

Reduction of AHI of more than 50% to below 15 events per hour, or normal (below 5 per hour);

3-months
SHER20 criteria defining responders to treatment
時間枠:3-months

Reduction of AHI of more than 50% to below 20 events per hour, or normal (below 5 per hour);

3-months
Gender-related response
時間枠:3-months

Responder rate according to gender (male vs female responders, percentage)

3-months
Cost-Effectiveness
時間枠:3 months

Cost-effectiveness of ZeusOSA compared to usual care (ongoing CPAP) in patients with low CPAP adherence, expressed as incremental cost-effectiveness ratios (ICERs). ICERs are a composite measure which will be derived from: proportion of responders, quality of life (EQ-5D-5L), and healthcare resource use/cost data.

3 months
Socioeconomic Group/Area-related response
時間枠:3-months

Responder rate according to socioeconomic area (Index of Multiple Deprivation decile 1-10), percentage

3-months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディチェア:Joerg Steier, PhD、Guy's & St Thomas' NHS Foundation Trust, London, UK

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月30日

一次修了 (推定)

2028年1月31日

研究の完了 (推定)

2028年9月1日

試験登録日

最初に提出

2025年12月17日

QC基準を満たした最初の提出物

2026年1月7日

最初の投稿 (実際)

2026年1月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月22日

QC基準を満たした最後の更新が送信されました

2026年9月16日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ZEUSi4i-1.0-03/12/25
  • NIHR209411 (その他の助成金/資金番号:National Institute for Health and Care Research (NIHR))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Pending ethics approval and medio-legal framework (GDPR)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。